This communication should include detailed description of the side effect (what symptoms are experienced, when they started, how severe they are), timing relative to IGF1 LR3 use (when was the last dose, how long after use did symptoms begin), any actions already taken (interventions tried, their effectiveness), and current status (whether symptoms are improving, stable, or worsening)
April 2025 We continue to await a decision on plaintiffs' appeal of Judge Cote's decision to grant summary judgment to the defendants
Neuroprotective effects of thymoquinone on the hippocampus in a rat model of traumatic brain injury
for the first time [55]
Reading the gaps in reverse points to what a stronger evidence base would require
Chen X, Guo W, Chang Y, Chen J, Kang P, Yi X, et al